Lung Cancers Today· @Lung_Cancers · X·· 2026-04-21Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Zoldonrasib showed “durable clinical efficacy” in patients with previously treated KRAS G12D NSCLC, according to an updated analysis of an ongoing phase 1 study presented at #AACR26 by
@riess_md
of
@UCD_Cancer
.
Read more:
https://
buff.ly/6W1FmMR
#lcsm #NSCLC #AACR2026
Heat 1 · 1 like · 0 replies · 0 reposts
Source: Lung Cancers Today · x.com